Literature DB >> 17709538

Neisseria meningitidis PorB, a TLR2 ligand, induces an antigen-specific eosinophil recall response: potential adjuvant for helminth vaccines?

Jennifer M Burke1, Lisa M Ganley-Leal, Asma Khatri, Lee M Wetzler.   

Abstract

Efficacious adjuvants are important components of new vaccines. The neisserial outer membrane protein, PorB, is a TLR2 ligand with unique adjuvant activity. We demonstrate that PorB promotes Th2-skewed cellular immune response to the model Ag, OVA, in mice, including Ag-specific recall eosinophil recruitment to the peritoneum. PorB induces chemokine secretion by myeloid cells using both TLR2-dependent and -independent mechanisms, suggesting that anatomical distribution of TLR2(+) cells may not be a limiting factor for potential vaccine strategies. The results from this study suggest that PorB, and other TLR2 ligands, may be ideal for use against pathogens where eosinophilia may be protective, such as parasitic helminths.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709538     DOI: 10.4049/jimmunol.179.5.3222

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Beyond empiricism: informing vaccine development through innate immunity research.

Authors:  Stuart M Levitz; Douglas T Golenbock
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

2.  The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity.

Authors:  Deana N Toussi; Xiuping Liu; Paola Massari
Journal:  Clin Vaccine Immunol       Date:  2012-05-23

3.  CD23b isoform expression in human schistosomiasis identifies a novel subset of activated B cells.

Authors:  Daniel Onguru; YanMei Liang; Jennifer Elliot; Pauline Mwinzi; Lisa Ganley-Leal
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

4.  Meningococcal Detoxified Outer Membrane Vesicle Vaccines Enhance Gonococcal Clearance in a Murine Infection Model.

Authors:  Kathryn A Matthias; Kristie L Connolly; Afrin A Begum; Ann E Jerse; Andrew N Macintyre; Gregory D Sempowski; Margaret C Bash
Journal:  J Infect Dis       Date:  2022-02-15       Impact factor: 7.759

5.  The contribution of Toll-like receptor 2 to the innate recognition of a Leishmania infantum silent information regulator 2 protein.

Authors:  Ricardo Silvestre; Ana M Silva; Anabela Cordeiro-da-Silva; Ali Ouaissi
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

6.  Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition.

Authors:  Christof Kattner; Deana N Toussi; Jan Zaucha; Lee M Wetzler; Nadine Rüppel; Ulrich Zachariae; Paola Massari; Mikio Tanabe
Journal:  J Struct Biol       Date:  2013-12-19       Impact factor: 2.867

7.  Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.

Authors:  Damiana Chiavolini; Susan Weir; John R Murphy; Lee M Wetzler
Journal:  Clin Vaccine Immunol       Date:  2008-07-09

8.  Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Authors:  Oliver Koeberling; Serena Giuntini; Anja Seubert; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2008-12-24

9.  Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant.

Authors:  Abel E Vasquez; Ricardo A Manzo; Daniel A Soto; Magaly J Barrientos; Aurora E Maldonado; Macarena Mosqueira; Anastasia Avila; Jorge Touma; Elsa Bruce; Paul R Harris; Alejandro Venegas
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 10.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.

Authors:  Deana N Toussi; Paola Massari
Journal:  Vaccines (Basel)       Date:  2014-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.